{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:54:07Z","timestamp":1770882847728,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During pregnancy, women may develop de novo sight-threatening chorioretinal diseases or experience exacerbations of these conditions. Examples include macular neovascularisation, diabetic macular oedema, and posterior uveitis. Ophthalmologists may not necessarily recommend the standard treatment for these disorders when they arise in pregnant women due to a lack of evidence regarding safety and potential risks of teratogenicity and fetotoxicity, and a lack of experience with managing this patient population. However, withholding treatment may lead to irreversible maternal vision loss. In this review, we discuss therapies that may need to be considered in these conditions, including steroids, intraocular pressure-lowering treatment for steroid-induced glaucoma, systemic immunosuppressants, and intravitreal anti-vascular endothelial growth factor agents. We discuss the evidence base behind these treatments in terms of safety in pregnancy, bringing in the obstetric perspective. We also discuss common misconceptions surrounding different modes of delivery in pregnant women with chorioretinal disease.<\/jats:p>","DOI":"10.1038\/s41433-025-04058-9","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:47:01Z","timestamp":1762501621000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of uveitic and chorioretinal conditions in pregnancy"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9300-573X","authenticated-orcid":false,"given":"Ariel Yuhan","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-4854","authenticated-orcid":false,"given":"Evita Evangelia","family":"Christou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine A.","family":"Kiire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Primrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Frise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-2814","authenticated-orcid":false,"given":"Samantha R.","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"4058_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100890","volume":"26","author":"R Franceschini","year":"2022","unstructured":"Franceschini R, Wicks SL. ClinicalTrials.Gov: pitfalls for pregnant women looking to enroll in studies. Contemp Clin Trials Commun. 2022;26:100890.","journal-title":"Contemp Clin Trials Commun"},{"key":"4058_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10928-020-09687-z","volume":"47","author":"M McKiever","year":"2020","unstructured":"McKiever M, Frey H, Costantine MM. Challenges in conducting clinical research studies in pregnant women. J Pharmacokinet Pharmacodyn. 2020;47:287\u201393.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4058_CR3","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.whi.2012.10.003","volume":"23","author":"MC Blehar","year":"2013","unstructured":"Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Women\u2019s Health Issues. 2013;23:e39\u201345.","journal-title":"Women\u2019s Health Issues"},{"key":"4058_CR4","unstructured":"Tommy\u2019s. Tommy\u2019s: The Pregnancy and Baby Charity. [cited 2025 Mar 18]. Miscarriage statistics. Available from: https:\/\/www.tommys.org\/baby-loss-support\/miscarriage-information-and-support\/miscarriage-statistics."},{"key":"4058_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","volume":"686","author":"H Dolk","year":"2010","unstructured":"Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349\u201364.","journal-title":"Adv Exp Med Biol"},{"key":"4058_CR6","unstructured":"NHS England Digital. NHS England Digital. [cited 2025 Mar 18]. NCARDRS Congenital Anomaly Official Statistics Report, 2020. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/ncardrs-congenital-anomaly-statistics-annual-data\/ncardrs-congenital-anomaly-statistics-report-2020."},{"key":"4058_CR7","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijms22062965","volume":"22","author":"A Ornoy","year":"2021","unstructured":"Ornoy A, Becker M, Weinstein-Fudim L, Ergaz Z. Diabetes during pregnancy: a maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. a clinical review. Int J Mol Sci. 2021;22:2965.","journal-title":"Int J Mol Sci"},{"key":"4058_CR8","unstructured":"Levy RA, Pinto CM, Domingues V, Jes\u00fas G de, Garc\u00eda-Carrasco M, Jes\u00fas NR de, et al. Systemic autoimmune diseases and pregnancy. In: Autoimmunity: from bench to bedside [Internet] [Internet]. El Rosario University Press; 2013 [cited 2025 Mar 18]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459481\/."},{"key":"4058_CR9","doi-asserted-by":"crossref","unstructured":"Ong AY, Kiire CA, Frise C, Bakr Y, de Silva SR. Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature. Eye. 2024;38:951\u201363.","DOI":"10.1038\/s41433-023-02811-6"},{"key":"4058_CR10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/bjophthalmol-2013-303358","volume":"97","author":"NPY Chiam","year":"2013","unstructured":"Chiam NPY, Hall AJH, Stawell RJ, Busija L, Lim LLP. The course of uveitis in pregnancy and postpartum. Br J Ophthalmol. 2013;97:1284\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4058_CR11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9394(03)00110-7","volume":"136","author":"PK Rabiah","year":"2003","unstructured":"Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol. 2003;136:91\u20138.","journal-title":"Am J Ophthalmol"},{"key":"4058_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09273940500557027","volume":"14","author":"LI Kump","year":"2006","unstructured":"Kump LI, Cervantes-Casta\u00f1eda RA, Androudi SN, Foster CS, Christen WG. Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium. Ocul Immunol Inflamm. 2006;14:99\u2013104.","journal-title":"Ocul Immunol Inflamm"},{"key":"4058_CR13","doi-asserted-by":"crossref","unstructured":"Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22:240\u201359.","DOI":"10.1093\/humupd\/dmv047"},{"key":"4058_CR14","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/AOG.0000000000005512","volume":"143","author":"AF Saad","year":"2024","unstructured":"Saad AF, Pacheco LD, Saade GR. Immunosuppressant medications in pregnancy. Obstet Gynecol. 2024;143:e94\u2013106.","journal-title":"Obstet Gynecol"},{"key":"4058_CR15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","volume":"43","author":"G Bandoli","year":"2017","unstructured":"Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43:489\u2013502.","journal-title":"Rheum Dis Clin North Am"},{"key":"4058_CR16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/01443615.2018.1525609","volume":"39","author":"A Takahashi","year":"2019","unstructured":"Takahashi A, Kita N, Tanaka Y, Tsuji S, One T, Ishiko A, et al. Effects of high-dose dexamethasone in postpartum women with class 1 haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Obstet Gynaecol. 2019;39:335\u20139.","journal-title":"J Obstet Gynaecol"},{"key":"4058_CR17","doi-asserted-by":"crossref","unstructured":"Fazelat A, Lashkari K. Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a pregnant patient. OPTH. 2011;5:439\u2013441.","DOI":"10.2147\/OPTH.S14584"},{"key":"4058_CR18","doi-asserted-by":"crossref","first-page":"1374.","DOI":"10.3390\/jpm12091374","volume":"12","author":"I Ben Ghezala","year":"2022","unstructured":"Ben Ghezala I, Mariet AS, Benzenine E, Bardou M, Bron AM, Gabrielle PH, et al. Association between obstetric complications and intravitreal anti-vascular endothelial growth factor agents or intravitreal corticosteroids. JPM. 2022;12:1374.","journal-title":"JPM"},{"key":"4058_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/eye.2000.20","volume":"14","author":"JA Quinlivan","year":"2000","unstructured":"Quinlivan JA, Beazley LD, Evans SF, Newnham JP, Dunlop SA. Retinal maturation is delayed by repeated, but not single, maternal injections of betamethasone in sheep. Eye. 2000;14:93\u20138.","journal-title":"Eye"},{"key":"4058_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bpobgyn.2008.06.005","volume":"22","author":"A Carlin","year":"2008","unstructured":"Carlin A, Alfirevic Z. Physiological changes of pregnancy and monitoring. Best Pr Res Clin Obstet Gynaecol. 2008;22:801\u201323.","journal-title":"Best Pr Res Clin Obstet Gynaecol"},{"key":"4058_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","volume":"58","author":"W Kiddee","year":"2013","unstructured":"Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291\u2013310.","journal-title":"Surv Ophthalmol"},{"key":"4058_CR22","first-page":"1274","volume":"24","author":"M Armaly","year":"1965","unstructured":"Armaly M, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24:1274\u20138.","journal-title":"Fed Proc"},{"key":"4058_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.eye.6702474","volume":"22","author":"R Sihota","year":"2008","unstructured":"Sihota R, Konkal VL, Dada T, Agarwal HC, Singh R. Prospective, long-term evaluation of steroid-induced glaucoma. Eye. 2008;22:26\u201330.","journal-title":"Eye"},{"key":"4058_CR24","first-page":"251584142110228","volume":"13","author":"R Kumari","year":"2021","unstructured":"Kumari R, Saha BC, Onkar A, Ambasta A, Kumari A. Management of glaucoma in pregnancy\u2014balancing safety with efficacy. Ther Adv Ophthalmol. 2021;13:25158414211022876.","journal-title":"Ther Adv Ophthalmol"},{"key":"4058_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/mpd.2001.111319","volume":"138","author":"RJ Berlin","year":"2001","unstructured":"Berlin RJ, Lee UT, Samples JR, Rich LF, Tang-Liu DDS, Sing KA, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138:441\u20133.","journal-title":"J Pediatr."},{"key":"4058_CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0002-9394(99)00083-5","volume":"128","author":"JO Carlsen","year":"1999","unstructured":"Carlsen JO, Zabriskie NA, Kwon YH, Barbe ME, Scott WE. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255\u20136.","journal-title":"Am J Ophthalmol"},{"key":"4058_CR27","first-page":"1684","volume":"9","author":"HS Sethi","year":"2016","unstructured":"Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol. 2016;9:1684\u201390.","journal-title":"Int J Ophthalmol"},{"key":"4058_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ICU.0000000000000029","volume":"25","author":"S Salim","year":"2014","unstructured":"Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol. 2014;25:93\u20137.","journal-title":"Curr Opin Ophthalmol"},{"key":"4058_CR29","unstructured":"Briggs GG, Freeman RK, Tower CV Brigg\u2019s Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk [Internet]. [cited 2025 Mar 18]. Available from: https:\/\/www.wolterskluwer.com\/en\/solutions\/ovid\/briggs-drugs-in-pregnancy-and-lactation-a-reference-guide-to-fetal-and-neonatal-risk-730."},{"key":"4058_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.plefa.2008.01.005","volume":"78","author":"NA Sharif","year":"2008","unstructured":"Sharif NA. Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins, Leukot Ess Fat Acids. 2008;78:199\u2013207.","journal-title":"Prostaglandins, Leukot Ess Fat Acids"},{"key":"4058_CR31","unstructured":"NHS. nhs.uk. 2023 [cited 2025 Mar 18]. Pregnancy, breastfeeding and fertility while using latanoprost. Available from: https:\/\/www.nhs.uk\/medicines\/latanoprost\/pregnancy-breastfeeding-and-fertility-while-using-latanoprost\/."},{"key":"4058_CR32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198111263052205","volume":"305","author":"PC Rubin","year":"1981","unstructured":"Rubin PC. Beta-blockers in pregnancy. N Engl J Med. 1981;305:1323\u20136.","journal-title":"N Engl J Med"},{"key":"4058_CR33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.111.00833","volume":"62","author":"MY Yakoob","year":"2013","unstructured":"Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin JM, Goodman JE, et al. The risk of congenital malformations associated with exposure to \u03b2-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62:375\u201381.","journal-title":"Hypertension"},{"key":"4058_CR34","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/aogs.14363","volume":"101","author":"IK S\u00f8rbye","year":"2022","unstructured":"S\u00f8rbye IK, Haualand R, Wiull H, Letting AS, Langes\u00e6ter E, Estensen ME. Maternal beta-blocker dose and risk of small-for gestational-age in women with heart disease. Acta Obstet et Gynecol Scand. 2022;101:794\u2013802.","journal-title":"Acta Obstet et Gynecol Scand"},{"key":"4058_CR35","doi-asserted-by":"crossref","first-page":"132234.","DOI":"10.1016\/j.ijcard.2024.132234","volume":"410","author":"KP Ramlakhan","year":"2024","unstructured":"Ramlakhan KP, Roos-Hesselink JW, Basso T, Greenslade J, Flint RB, Krieger EV, et al. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC). Int J Cardiol. 2024;410:132234.","journal-title":"Int J Cardiol"},{"key":"4058_CR36","unstructured":"NHS. nhs.uk. 2022 [cited 2025 Mar 23]. Pregnancy, breastfeeding and fertility while using timolol eye drops. Available from: https:\/\/www.nhs.uk\/medicines\/timolol-eye-drops\/pregnancy-breastfeeding-and-fertility-while-using-timolol-eye-drops\/."},{"key":"4058_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/tera.1420010107","volume":"1","author":"JG Wilson","year":"1968","unstructured":"Wilson JG, Maren TH, Takano K, Ellison A. Teratogenic action of carbonic anhydrase inhibitors in the rat. Teratology. 1968;1:51\u201360.","journal-title":"Teratology"},{"key":"4058_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNO.0b013e3182594001","volume":"33","author":"J Falardeau","year":"2013","unstructured":"Falardeau J, Lobb BM, Golden S, Maxfield SD, Tanne E. The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol. 2013;33:9\u201312.","journal-title":"J Neuroophthalmol"},{"key":"4058_CR39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcjo.2021.05.006","volume":"57","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Pruet CM, Fang C, Khanna CL. Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma. Can J Ophthalmol. 2022;57:277\u201383.","journal-title":"Can J Ophthalmol"},{"key":"4058_CR40","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2019.11.017","volume":"127","author":"AP Khawaja","year":"2020","unstructured":"Khawaja AP, Campbell JH, Kirby N, Chandwani HS, Keyzor I, Parekh M, et al. Real-world outcomes of selective laser trabeculoplasty in the United Kingdom. Ophthalmology. 2020;127:748\u201357.","journal-title":"Ophthalmology"},{"key":"4058_CR41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ogla.2019.12.004","volume":"3","author":"A Belkin","year":"2020","unstructured":"Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM. A Practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma. 2020;3:79\u201389.","journal-title":"Ophthalmol Glaucoma"},{"key":"4058_CR42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.farma.2022.12.005","volume":"47","author":"O Ibarra Barrueta","year":"2023","unstructured":"Ibarra Barrueta O, Garc\u00eda Mart\u00edn E, L\u00f3pez S\u00e1nchez P, Ram\u00edrez Herr\u00e1iz E, Merino Boh\u00f3rquez V, Ais Larisgoitia A. Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases. Farm Hosp. 2023;47:39\u201349.","journal-title":"Farm Hosp"},{"key":"4058_CR43","doi-asserted-by":"crossref","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","volume":"44","author":"EA Pinheiro","year":"2020","unstructured":"Pinheiro EA, Stika CS. Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care. Semin Perinatol. 2020;44:151221.","journal-title":"Semin Perinatol"},{"key":"4058_CR44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/bdra.20583","volume":"85","author":"BJ Cleary","year":"2009","unstructured":"Cleary BJ, K\u00e4ll\u00e9n B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647\u201354.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"4058_CR45","first-page":"1401","volume":"57","author":"A Natekar","year":"2011","unstructured":"Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57:1401\u20132.","journal-title":"Can Fam Physician"},{"key":"4058_CR46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","volume":"95","author":"MF Hebert","year":"2013","unstructured":"Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95:908\u201315.","journal-title":"Transplantation"},{"key":"4058_CR47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","volume":"131","author":"A Puchner","year":"2019","unstructured":"Puchner A, Gr\u00f6chenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, et al. Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian societies of gastroenterology and hepatology and rheumatology and rehabilitation. Wien Klin Wochenschr. 2019;131:29\u201344.","journal-title":"Wien Klin Wochenschr"},{"key":"4058_CR48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","volume":"53","author":"KL Hyrich","year":"2014","unstructured":"Hyrich KL, Verstappen SMM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53:1377\u201385.","journal-title":"Rheumatology"},{"key":"4058_CR49","unstructured":"NPEU Clinical Trials Unit. MAMA: Information for Health Professionals [Internet]. [cited 2025 Mar 17]. Available from: https:\/\/www.npeu.ox.ac.uk\/mama\/health-professionals."},{"key":"4058_CR50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286\u2013e24.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4058_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312.","journal-title":"J Reprod Immunol"},{"key":"4058_CR52","unstructured":"EMC. Cimzia 200 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)\u2014(emc) [Internet]. [cited 2025 Mar 17]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4450\/smpc#gref."},{"key":"4058_CR53","doi-asserted-by":"crossref","first-page":"e0223603","DOI":"10.1371\/journal.pone.0223603","volume":"14","author":"CD Chambers","year":"2019","unstructured":"Chambers CD, Johnson DL, Xu R, Luo Y, Lopez-Jimenez J, Adam MP, et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS One. 2019;14:e0223603.","journal-title":"PLoS One"},{"key":"4058_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2011.05.009","volume":"32","author":"N Djokanovic","year":"2011","unstructured":"Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93\u20137.","journal-title":"Reprod Toxicol"},{"key":"4058_CR55","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy. Neurol Neuroimmunol Neuroinflammation. 2018;5:e453","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4058_CR56","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/14397595.2016.1147405","volume":"26","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016;26:667\u201371.","journal-title":"Mod Rheumatol"},{"key":"4058_CR57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","volume":"46","author":"M Hoeltzenbein","year":"2016","unstructured":"Hoeltzenbein M, Beck E, Rajwanshi R, G\u00f8testam Skorpen C, Berber E, Schaefer C, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016;46:238\u201345.","journal-title":"Semin Arthritis Rheum"},{"key":"4058_CR58","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","volume":"61","author":"B Goulden","year":"2022","unstructured":"Goulden B, Chua N, Parker E, Giles I. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatol (Oxf). 2022;61:3902\u20136.","journal-title":"Rheumatol (Oxf)"},{"key":"4058_CR59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2352-4642(23)00136-0","volume":"7","author":"T Fitzpatrick","year":"2023","unstructured":"Fitzpatrick T, Alsager K, Sadarangani M, Pham-Huy A, Murgu\u00eda-Favela L, Morris SK, et al. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health. 2023;7:648\u201356.","journal-title":"Lancet Child Adolesc Health"},{"key":"4058_CR60","unstructured":"Gov.uk. GOV.UK. [cited 2025 Mar 18]. Updates to Public Health England\u2019s Green Book chapter on live attenuated vaccines. Available from: https:\/\/www.gov.uk\/drug-safety-update\/updates-to-public-health-england-s-green-book-chapter-on-live-attenuated-vaccines."},{"key":"4058_CR61","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ecco-jcc\/jjad005","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Chaparro M. Vaccines in children exposed to biological agents in utero and\/or during breastfeeding: are they effective and safe? J Crohns Colitis. 2023;17:995\u20131009.","journal-title":"J Crohns Colitis"},{"key":"4058_CR62","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"4058_CR63","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","volume":"62","author":"MD Russell","year":"2023","unstructured":"Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatol. 2023;62:e48\u201388.","journal-title":"Rheumatol"},{"key":"4058_CR64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","volume":"4","author":"LA Coscia","year":"2015","unstructured":"Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4:42\u201355.","journal-title":"J Pediatr Genet"},{"key":"4058_CR65","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajmg.a.35223","volume":"158A","author":"M Hoeltzenbein","year":"2012","unstructured":"Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A:588\u201396.","journal-title":"Am J Med Genet A"},{"key":"4058_CR66","unstructured":"Versus Arthritis. Drug Information: Methotrexate [Internet]. [cited 2025 Aug 4]. Available from: https:\/\/www.versusarthritis.org\/media\/23514\/methotrexate-information-booklet-april2021.pdf."},{"key":"4058_CR67","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","volume":"48","author":"M Mouyis","year":"2019","unstructured":"Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum. 2019;48:911\u201320.","journal-title":"Semin Arthritis Rheum"},{"key":"4058_CR68","unstructured":"Garweg JG, Straessle KA. Janus kinase inhibitors as a third-line therapy for refractory endogenous noninfectious uveitis. Ocul Immunol Inflamm. 2024;6:1\u20138."},{"key":"4058_CR69","doi-asserted-by":"crossref","unstructured":"Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hern\u00e1ndez-Rodr\u00edguez J, Pelegr\u00edn L, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front Med [Internet]. 2024 Aug 23 [cited 2025 Aug 5];11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1439338\/full.","DOI":"10.3389\/fmed.2024.1489092"},{"key":"4058_CR70","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10792-020-01610-2","volume":"41","author":"M Naderan","year":"2021","unstructured":"Naderan M, Sabzevary M, Rezaii K, Banafshehafshan A, Hantoushzadeh S. Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective. Int Ophthalmol. 2021;41:743\u201351.","journal-title":"Int Ophthalmol"},{"key":"4058_CR71","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/IAE.0000000000001200","volume":"36","author":"ZH Peracha","year":"2016","unstructured":"Peracha ZH, Rosenfeld PJ. Anti\u2013vascular endothelial growth factor therapy in pregnancy: what we know, what we don\u2019t know, and what we don\u2019t know we don\u2019t know. Retina. 2016;36:1413\u20137.","journal-title":"Retina"},{"key":"4058_CR72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40123-021-00416-4","volume":"11","author":"D Ratra","year":"2022","unstructured":"Ratra D, Roy K, Giridhar S, Madaan S. Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation. Ophthalmol Ther. 2022;11:135\u201349.","journal-title":"Ophthalmol Ther"},{"key":"4058_CR73","unstructured":"Roche. Avastin 25mg\/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) [Internet]. 2021 [cited 2021 Jun 13]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3885."},{"key":"4058_CR74","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847\u201358.","journal-title":"Retina"},{"key":"4058_CR75","unstructured":"Bayer. Eylea 40mg\/ml solution for injection in a vial - Summary of Product Characteristics (SmPC) [Internet]. 2021 [cited 2021 Jun 13]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2879\/smpc."},{"key":"4058_CR76","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2147\/PPA.S427209","volume":"17","author":"A Taloni","year":"2023","unstructured":"Taloni A, Coco G, Rastelli D, Buffon G, Scorcia V, Giannaccare G. Safety and efficacy of dexamethasone intravitreal implant given either first-line or second-line in diabetic macular edema. Patient Prefer Adherence. 2023;17:3307\u201329.","journal-title":"Patient Prefer Adherence"},{"key":"4058_CR77","volume":"2015","author":"I Ece","year":"2015","unstructured":"Ece I, Vatansev C, Kucukkartallar T, Tekin A, Kartal A, Okka M. The increase of intra-abdominal pressure can affect intraocular pressure. Biomed Res Int. 2015;2015:986895.","journal-title":"Biomed Res Int"},{"key":"4058_CR78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1258\/shorts.2011.010107","volume":"2","author":"E Papamichael","year":"2011","unstructured":"Papamichael E, Aylward GW, Regan L. Obstetric opinions regarding the method of delivery in women that have had surgery for retinal detachment. JRSM Short Rep. 2011;2:24.","journal-title":"JRSM Short Rep"},{"key":"4058_CR79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcjo.2014.10.015","volume":"50","author":"H Chiu","year":"2015","unstructured":"Chiu H, Steele D, McAlister C, Lam WC. Delivery recommendations for pregnant females with risk factors for rhegmatogenous retinal detachment. Can J Ophthalmol. 2015;50:11\u20138.","journal-title":"Can J Ophthalmol"},{"key":"4058_CR80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.joco.2016.09.010","volume":"29","author":"SF Mohammadi","year":"2017","unstructured":"Mohammadi SF, Letafat-Nejad M, Ashrafi E, Delshad-Aghdam H. A survey of ophthalmologists and gynecologists regarding termination of pregnancy and choice of delivery mode in the presence of eye diseases. J Curr Ophthalmol. 2017;29:126\u201332.","journal-title":"J Curr Ophthalmol"},{"key":"4058_CR81","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/BF00404712","volume":"233","author":"D Landau","year":"1995","unstructured":"Landau D, Seelenfreund MH, Tadmor O, Silverstone BZ, Diamant Y. The effect of normal childbirth on eyes with abnormalities predisposing to rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1995;233:598\u2013600.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4058_CR82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/IAE.0000000000003909","volume":"44","author":"A Shemer","year":"2024","unstructured":"Shemer A, Zloto K, Peretz Z, Eting E, Or L, Pras E, et al. Rates of recurrent retinal detachment after vaginal versus cesarean deliveries: a retrospective analysis and review of the literature. Retina. 2024;44:78.","journal-title":"Retina"},{"key":"4058_CR83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/ICB.0000000000000997","volume":"16","author":"S Risseeuw","year":"2022","unstructured":"Risseeuw S, Yildirim H, Spiering W, Imhof SM, van Leeuwen R, Ossewaarde-van Norel J. Is vaginal delivery harmful to patients with pseudoxanthoma elasticum? Retin Cases Brief Rep. 2022;16:422\u20135.","journal-title":"Retin Cases Brief Rep"},{"key":"4058_CR84","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-021-01814-9","volume":"21","author":"K Bitton","year":"2021","unstructured":"Bitton K, Bacquet JL, Amoroso F, Mrejen S, Paques M, Souied EH. Immediate post partum macular subretinal bleeding in a highly myopic patient: a case report. BMC Ophthalmol. 2021;21:54.","journal-title":"BMC Ophthalmol"},{"key":"4058_CR85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/aos.14898","volume":"100","author":"EL de Groot","year":"2022","unstructured":"de Groot EL, van Huet RAC, Bloemenkamp KWM, de Boer JH, Ossewaarde-van Norel J. Idiopathic multifocal choroiditis and punctate inner choroidopathy: an evaluation in pregnancy. Acta Ophthalmol. 2022;100:82\u20138.","journal-title":"Acta Ophthalmol"},{"key":"4058_CR86","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.12659\/MSM.916479","volume":"25","author":"M Sapu\u0142a-Grabowska","year":"2019","unstructured":"Sapu\u0142a-Grabowska M, Ciszewska J, Brydak-Godowska J, Sawa A, Laszewicz P, Bartha E, et al. Delivery in myopic women: a comparison of mode of delivery in years 1990, 2000, and 2010. Med Sci Monit. 2019;25:7715\u20139.","journal-title":"Med Sci Monit"},{"key":"4058_CR87","doi-asserted-by":"crossref","first-page":"100314","DOI":"10.1016\/j.clinme.2025.100314","volume":"25","author":"AY Ong","year":"2025","unstructured":"Ong AY, Kiire CA, de Silva SR, Frise C. Collaborative care for pregnant women with eye conditions. Clin Med. 2025;25:100314.","journal-title":"Clin Med"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04058-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:20:28Z","timestamp":1767424828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4058"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04058-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WT has a consultancy agreement with Roche unrelated to the submitted work, which has not influenced the content or conclusions of the review. CF is the Editor-in-Chief of Obstetric Medicine: The Medicine of Pregnancy. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}